Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Mannkind Corp
(NQ:
MNKD
)
4.320
+0.010 (+0.23%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,897,796
Open
4.350
Bid (Size)
4.210 (1)
Ask (Size)
4.380 (10)
Prev. Close
4.310
Today's Range
4.225 - 4.450
52wk Range
3.170 - 5.750
Shares Outstanding
264,305,532
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
MannKind (MNKD) Q1 2024 Earnings Call Transcript
May 09, 2024
MNKD earnings call for the period ending March 31, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
MNKD Stock Earnings: MannKind Beats EPS, Beats Revenue for Q1 2024
May 08, 2024
MNKD stock results show that MannKind beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Performance
YTD
+10.20%
+10.20%
1 Month
+1.89%
+1.89%
3 Month
+23.08%
+23.08%
6 Month
+25.95%
+25.95%
1 Year
+3.10%
+3.10%
More News
Read More
MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
May 08, 2024
From
MannKind
Via
GlobeNewswire
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
May 06, 2024
From
MannKind
Via
GlobeNewswire
Earnings Scheduled For February 27, 2024
February 27, 2024
Via
Benzinga
MannKind Earnings Preview
February 26, 2024
Via
Benzinga
MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
May 01, 2024
From
MannKind
Via
GlobeNewswire
MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
April 30, 2024
From
MannKind
Via
GlobeNewswire
MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease
April 29, 2024
From
MannKind
Via
GlobeNewswire
MannKind Repays Certain Debt Obligations
April 03, 2024
From
MannKind
Via
GlobeNewswire
MannKind Announces CFO Transition
March 26, 2024
From
MannKind
Via
GlobeNewswire
EQT, Genie Energy And Other Big Stocks Moving Lower On Monday
March 11, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 11, 2024
Via
Benzinga
Exposures
Product Safety
What's Going On With MannKind Stock?
March 11, 2024
Via
Benzinga
INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps
March 11, 2024
From
MannKind
Via
GlobeNewswire
Cramer Says Sprout Social Is In A 'Hot Spot,' But This Energy Stock Is 'Too Down And Out'
March 08, 2024
Via
Benzinga
MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8
March 05, 2024
From
MannKind
Via
GlobeNewswire
MannKind Corporation Announces Participation at Upcoming Conferences
March 04, 2024
From
MannKind
Via
GlobeNewswire
MannKind (MNKD) Q4 2023 Earnings Call Transcript
February 28, 2024
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update
February 27, 2024
From
MannKind
Via
GlobeNewswire
MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024
February 20, 2024
From
MannKind
Via
GlobeNewswire
MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®
February 15, 2024
From
MannKind
Via
GlobeNewswire
3 Biotech Stocks to Sell in January Before They Crash and Burn
January 25, 2024
Via
InvestorPlace
Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
January 02, 2024
Via
Benzinga
MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million
January 02, 2024
From
MannKind
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.